Risk factors for vancomycin treatment failure in heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia

被引:0
|
作者
Yun, Ji Hyun [1 ]
Chang, Euijin [2 ]
Bae, Seongman [2 ,3 ]
Jung, Jiwon [2 ]
Kim, Min Jae [2 ]
Chong, Yong Pil [2 ]
Kim, Sung-Han [2 ]
Choi, Sang-Ho [2 ]
Lee, Sang-Oh [2 ]
Kim, Yang Soo [2 ,3 ]
机构
[1] Konkuk Univ, Sch Med, Dept Internal Med, Div Infect Dis,Med Ctr, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Div Infect Dis, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Ctr Antimicrobial Resistance & Microbial Genet, Seoul, South Korea
来源
MICROBIOLOGY SPECTRUM | 2024年 / 12卷 / 08期
关键词
hVISA; vancomycin; treatment failure; risk factors; age; severity; minimal inhibitory concentration; MINIMUM INHIBITORY CONCENTRATIONS; METHICILLIN-RESISTANT; CLINICAL-FEATURES; INFECTIONS; STRAINS; HETERORESISTANCE; SUSCEPTIBILITY; DEFINITION; CRITERIA;
D O I
10.1128/spectrum.00333-24
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The incidence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) infection is increasing and is associated with vancomycin treatment failures. However, studies investigating the risk factors for treatment failure in hVISA infection are limited. Patients with hVISA bacteremia treated with vancomycin over 7 days between August 2008 and June 2020 were enrolled in this study. Clinical and microbiological characteristics were compared between vancomycin treatment failure and success groups to identify the risk factors for vancomycin treatment failure. Among the 180 patients with hVISA bacteremia, 102 patients treated with vancomycin over 7 days were included. Vancomycin treatment failed in 80 (78%) patients. Patients in the vancomycin treatment failure group were older (P < 0.001) and more frequently had solid cancer (P = 0.04) than those in the vancomycin treatment success group. Solid organ transplantation (SOT) was more frequent (P < 0.001) in the vancomycin treatment success group. The Charlson comorbidity index (P = 0.01) and Acute Physiology and Chronic Health Evaluation II scores (P < 0.001) were higher in the vancomycin treatment failure group. In multivariate analysis, independent risk factors for vancomycin treatment failure were old age and severity of bacteremia. SOT and vancomycin minimal inhibitory concentration (MIC) <= 1.0 mg/L using the broth microdilution (BMD) method were associated with successful vancomycin treatment. Old age and infection severity were independent risk factors for vancomycin treatment failure. Vancomycin MIC using the BMD method is an important risk factor for vancomycin treatment failure, and its use should be considered in hVISA bacteremia. IMPORTANCE In this study, we assessed the clinical and microbiological characteristics of heterogeneous vancomycin-intermediated Staphylococcus aureus (hVISA) bacteremia and identified risk factors for vancomycin treatment failure. We found that advanced age and severity of infection were independent risk factors for vancomycin treatment failure. On the other hand, solid organ transplantation and a low vancomycin minimal inhibitory concentration were associated with successful vancomycin treatment. This study highlights the importance of vancomycin minimal inhibitory concentration in hVISA bacteremia.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Risk factors for vancomycin treatment failure in heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia (vol 12, e00333-24, 2024)
    Yun, Ji Hyun
    Chang, Euijin
    Bae, Seongman
    Jung, Jiwon
    Kim, Min Jae
    Chong, Yong Pil
    Kim, Sung-Han
    Choi, Sang-Ho
    Lee, Sang-Oh
    Kim, Yang Soo
    MICROBIOLOGY SPECTRUM, 2025,
  • [2] Clinical and Microbiologic Analysis of the Risk Factors for Mortality in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bacteremia
    Chong, Yong Pil
    Park, Ki-Ho
    Kim, Eun Sil
    Kim, Mi-Na
    Kim, Sung-Han
    Lee, Sang-Oh
    Choi, Sang-Ho
    Jeong, Jin-Yong
    Woo, Jun Hee
    Kim, Yang Soo
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (06) : 3541 - 3547
  • [3] Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus
    Charles, PGP
    Ward, PB
    Johnson, PDR
    Howden, BP
    Grayson, ML
    CLINICAL INFECTIOUS DISEASES, 2004, 38 (03) : 448 - 451
  • [4] Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis
    Moore, MR
    Perdreau-Remington, F
    Chambers, HF
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (04) : 1262 - 1266
  • [5] Selection of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus by Imipenem
    Katayama, Yuki
    Murakami-Kuroda, Hiroko
    Cui, Longzhu
    Hiramatsu, Keiichi
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (08) : 3190 - 3196
  • [6] The incidence of heterogeneous vancomycin-intermediate Staphylococcus aureus correlated with increase of vancomycin MIC
    Chen, Hongbin
    Liu, Yudong
    Sun, Wenjia
    Chen, Minjun
    Wang, Hui
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2011, 71 (03) : 301 - 303
  • [7] Vancomycin-intermediate resistance in Staphylococcus aureus
    Hiramatsu, Keiichi
    Kayayama, Yuki
    Matsuo, Miki
    Aiba, Yoshifumi
    Saito, Michie
    Hishinuma, Tomomi
    Iwamoto, Akira
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2014, 2 (04) : 213 - 224
  • [8] Vancomycin-intermediate Staphylococcus aureus in Korea
    Kim, MN
    Pai, CH
    Woo, JH
    Ryu, JS
    Hiramatsu, K
    JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (10) : 3879 - 3881
  • [9] Survivability and fitness cost of heterogeneous vancomycin-intermediate Staphylococcus aureus
    Singh, Avinash
    Singh, Sanjay
    Singh, Jyoti
    Rahman, Mohibur
    Pathak, Ashutosh
    Prasad, Kashi Nath
    INDIAN JOURNAL OF MEDICAL MICROBIOLOGY, 2017, 35 (03) : 415 - 416
  • [10] Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates
    Zhang, Shanshan
    Sun, Xiaoxi
    Chang, Wenjiao
    Dai, Yuanyuan
    Ma, Xiaoling
    PLOS ONE, 2015, 10 (08):